ALK and non-small cell lung carcinoma: Since a previous study found that ceritinib was effective in patients with NSCLC treated with first-line alectinib, our results are in line with expectations about rechallenging with ALK-TKIs.34 We could not examine the molecular mechanism of resistance to previous ALK-TKI treatment or the efficacy of lorlatinib, a third-generation ALK-TKI.